Survey Report on China Abiraterone Markets 2016-2020 and 2021-2025: A CYP17 Inhibitor, Mainly Used Clinically to Treat Patients with Prostate Cancer

0

DUBLIN, March 07, 2022–(BUSINESS WIRE)–The “Chinese Abiraterone Market Survey Report 2021-2025” report has been added to from ResearchAndMarkets.com offer.

Abiraterone is a CYP17 inhibitor, primarily used clinically to treat patients with prostate cancer. Its product ZYTIGA was developed by Janssen-Cilag International NV (subsidiary of Johnson & Johnson). In 2015 Abiraterone entered the Chinese market.

The analyst analyzes that from 2021 to 2025, Abiraterone sales in China will continue to grow as the COVID-19 outbreak improves. According to data from the National Cancer Registration Institute of China, prostate cancer has become the most common tumor in male urinary malignancies since 2008. As the incidence and mortality of this cancer continue to increase increase, its sales will also increase.

As of 2020, in addition to Janssen-Cilag International NV, the main abiraterone manufacturers in China are Chengdu Suncadia Medicine Co., Ltd., Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Jiangxi Shanxiang Pharmaceutical Co., ltd. and Qilu Pharmaceutical Co., Ltd.

According to the market research, from 2016 to 2019, Abiraterone sales in the Chinese market showed an upward trend. In 2017, the price of Abiraterone dropped and it was included in China’s national medical insurance. Therefore, Abiraterone sales in the Chinese market increased most significantly from 2017 to 2019.

The annual revenue in 2019 is CNY 566.84 million, more than 30 times that of 2016. The COVID-19 outbreak in 2020 impacted the overall diagnostics business and of Chinese hospitals, so the sales value of Abiraterone in the Chinese market decreased slightly in 2020.

The sales value CAGR of Abiraterone in the Chinese market from 2016 to 2020 is 140.7%.

Topics Covered:

  • The impact of COVID-19 on the Chinese abiraterone market

  • Abiraterone sales value in China 2016-2020

  • Competitive Landscape of Chinese Abiraterone Market

  • Abiraterone price in China

  • Abiraterone Price in China by Regions and Manufacturers

  • Analysis of factors affecting the development of the Chinese abiraterone market

  • China Abiraterone Market Outlook 2021 to 2025

Main topics covered:

1 Relevant Concepts of Abiraterone

1.1 Indications for abiraterone

1.2 Abiraterone Development in China

1.3 Government approval of abiraterone in China

1.4 The impact of COVID-19 on Abiraterone sales in China

2 China Abiraterone Sales, 2016-2020

2.1 Abiraterone Sales Value

2.1.1 Overall sales value

2.1.2 Sales Value by Regions

2.2 Abiraterone Sales Volume

2.2.1 Overall Sales Volume

2.2.2 Sales Volume by Regions

2.3 China Abiraterone Sales by Dosage Form, 2016-2020

2.3.1 Tablet

2.3.2 Analysis of other dosage forms

3 Analysis of Abiraterone Key Manufacturers in China, 2016-2020

3.1 Abiraterone Major Manufacturers Market Share Analysis

3.1.1 Market Share Survey by Sales Value

3.1.2 Market Share Survey by Sales Volume

3.2 Janssen-Cilag International SA(BE)

3.2.1 Company profile

3.2.2 ZYTIGA (Abiraterone by Janssen-Cilag International NV(BE)) Sales in China

3.3 Chengdu Suncadia Medicine Co., Ltd.

3.3.1 Company Profile

3.3.2 Aisente (Chengdu Suncadia Medicine Co., Ltd. Abiraterone) Sales in China

3.4 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

3.4.1 Company Profile

3.4.2 China Qingkeshu (Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Abiraterone) Sales

3.5 Jiangxi Shanxiang Pharmaceutical Co., Ltd.

3.5.1 Business Profile

3.5.2 China Abiraterone (Jiangxi Shanxiang Pharmaceutical Co., Ltd.’s Abiraterone) Sales

3.6 Qilu Pharmaceutical Co., Ltd.

3.6.1 Company Profile

3.6.2 China Zhuorong (Abiraterone by Qilu Pharmaceutical Co., Ltd.) Sales

4 Abiraterone Price for Different Manufacturers in China, 2020-2021

4.1 Janssen-Cilag International NV(BE) (ZYTIGA)

4.2 Chengdu Suncadia Medicine Co., Ltd. (Aisente)

4.3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Qingkeshu)

4.4 Jiangxi Shanxiang Pharmaceutical Co., Ltd.

4.5 Qilu Pharmaceutical Co., Ltd. (Zhuorong)

5 China Abiraterone Market Outlook, 2021-2025

5.1 Influencing Factors of China Abiraterone Market Development

5.1.1 The impact of COVID-19 on the Chinese abiraterone market

5.1.2 Market Drivers and Opportunities

5.1.3 Market Threats and Challenges

5.2 Market Size Forecast

5.3 Market Trend Forecast

For more information on this report, visit https://www.researchandmarkets.com/r/vhvzf7

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220307005811/en/

contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Officer
[email protected]

For EST business hours, call 1-917-300-0470
For US/CAN call toll free 1-800-526-8630
For GMT office hours call +353-1-416-8900

Share.

Comments are closed.